Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)

Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also benefit from EGFR inhibitors (Merck & Co. / Eli Lilly’s Erbitux and Amgen’s Vectibix), which are recommended for first-line treatment of patients with left-sided tumors. Additional targeted therapies for specific molecular subtypes have been developed: immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo and Yervoy) for MSI-high and/or MMR-deficient tumors, BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi) for BRAF V600E-mutated tumors, KRAS inhibitors (Bristol Myers Squibb’s Krazati and Amgen´s Lumakras) for KRAS G12C-mutated tumors and HER2-targeted agents, (Chugai’s Perjeta and trastuzumab and Seagen’s Tukysa) available in some markets for HER2-positive metastatic disease. Therapies in late-phase development aim to address additional genomic alterations, such as c-MET overexpression, expand the pool of KRAS inhibitors for KRAS G12C-mutated tumors and anti-EGFR-targeted therapies for left- and right-sided RAS/BRAF wild-type tumors, and evaluate novel immunotherapy-based approaches for treating MSS and/or pMMR tumors.

Questions answered

• How large are the drug-treatable colorectal cancer populations?
• How do patient populations differ by disease stage and key biomarkers?
• What are interviewed experts’ views on current and emerging late-phase therapies?

Geography: United States, EU5, Japan.

Primary research: Country-specific interviews with thought-leading medical oncologists; survey data collected for this and other Clarivate research

Epidemiology: Diagnosed and recurrent incidence of colorectal cancer; drug-treatable and -treated cases by country, disease stage, tumor side, BRAF status, and RAS status.

Forecast: 10-year, annualized, drug-level sales and patient share of key colorectal cancer therapies through 2034, segmented by brands / generics and epidemiological subpopulations.

Drug treatments: Coverage of key current and emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.